Global Age-relatedMacularDegeneration (ARMD) Drugs Market Research Report 2024(Status and Outlook)
Report Overview:
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size was estimated at USD 8017.89 million in 2023 and is projected to reach USD 9629.68 million by 2029, exhibiting a CAGR of 3.10% during the forecast period.
This report provides a deep insight into the global Age-relatedMacularDegeneration (ARMD) Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Age-relatedMacularDegeneration (ARMD) Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Age-relatedMacularDegeneration (ARMD) Drugs market in any manner.
Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Market Segmentation (by Type)
Anti VEGF Drugs
Photosensitive Drugs
Others
Market Segmentation (by Application)
Exudative ARMD
Atrophy ARMD
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Age-relatedMacularDegeneration (ARMD) Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size was estimated at USD 8017.89 million in 2023 and is projected to reach USD 9629.68 million by 2029, exhibiting a CAGR of 3.10% during the forecast period.
This report provides a deep insight into the global Age-relatedMacularDegeneration (ARMD) Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Age-relatedMacularDegeneration (ARMD) Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Age-relatedMacularDegeneration (ARMD) Drugs market in any manner.
Global Age-relatedMacularDegeneration (ARMD) Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Roche
Regeneron Pharmaceuticals
Bayer
Santen Oy
Kanghong Pharmaceuticals
Novartis
Eli Lilly and Company
TRACON Pharmaceuticals
Pfizer
GSK
BIOCAD
Market Segmentation (by Type)
Anti VEGF Drugs
Photosensitive Drugs
Others
Market Segmentation (by Application)
Exudative ARMD
Atrophy ARMD
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Age-relatedMacularDegeneration (ARMD) Drugs Market
- Overview of the regional outlook of the Age-relatedMacularDegeneration (ARMD) Drugs Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Age-relatedMacularDegeneration (ARMD) Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Age-relatedMacularDegeneration (ARMD) Drugs
1.2 Key Market Segments
1.2.1 Age-relatedMacularDegeneration (ARMD) Drugs Segment by Type
1.2.2 Age-relatedMacularDegeneration (ARMD) Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Manufacturers (2019-2024)
3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Age-relatedMacularDegeneration (ARMD) Drugs Sales Sites, Area Served, Product Type
3.6 Age-relatedMacularDegeneration (ARMD) Drugs Market Competitive Situation and Trends
3.6.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Age-relatedMacularDegeneration (ARMD) Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Age-relatedMacularDegeneration (ARMD) Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Type (2019-2024)
6.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Price by Type (2019-2024)
7 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Sales by Application (2019-2024)
7.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Growth Rate by Application (2019-2024)
8 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET SEGMENTATION BY REGION
8.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region
8.1.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region
8.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Roche
9.1.1 Roche Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.1.2 Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.1.4 Roche Business Overview
9.1.5 Roche Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
9.1.6 Roche Recent Developments
9.2 Regeneron Pharmaceuticals
9.2.1 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.2.2 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.2.4 Regeneron Pharmaceuticals Business Overview
9.2.5 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
9.2.6 Regeneron Pharmaceuticals Recent Developments
9.3 Bayer
9.3.1 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.3.2 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.3.4 Bayer Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
9.3.5 Bayer Business Overview
9.3.6 Bayer Recent Developments
9.4 Santen Oy
9.4.1 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.4.2 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.4.4 Santen Oy Business Overview
9.4.5 Santen Oy Recent Developments
9.5 Kanghong Pharmaceuticals
9.5.1 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.5.2 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.5.4 Kanghong Pharmaceuticals Business Overview
9.5.5 Kanghong Pharmaceuticals Recent Developments
9.6 Novartis
9.6.1 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.6.2 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.6.4 Novartis Business Overview
9.6.5 Novartis Recent Developments
9.7 Eli Lilly and Company
9.7.1 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.7.2 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.7.4 Eli Lilly and Company Business Overview
9.7.5 Eli Lilly and Company Recent Developments
9.8 TRACON Pharmaceuticals
9.8.1 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.8.2 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.8.4 TRACON Pharmaceuticals Business Overview
9.8.5 TRACON Pharmaceuticals Recent Developments
9.9 Pfizer
9.9.1 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.9.2 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.9.4 Pfizer Business Overview
9.9.5 Pfizer Recent Developments
9.10 GSK
9.10.1 GSK Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.10.2 GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.10.4 GSK Business Overview
9.10.5 GSK Recent Developments
9.11 BIOCAD
9.11.1 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.11.2 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.11.4 BIOCAD Business Overview
9.11.5 BIOCAD Recent Developments
10 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET FORECAST BY REGION
10.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast
10.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Region
10.2.4 South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Age-relatedMacularDegeneration (ARMD) Drugs by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Age-relatedMacularDegeneration (ARMD) Drugs by Type (2025-2030)
11.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Age-relatedMacularDegeneration (ARMD) Drugs by Type (2025-2030)
11.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) Forecast by Application
11.2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Age-relatedMacularDegeneration (ARMD) Drugs
1.2 Key Market Segments
1.2.1 Age-relatedMacularDegeneration (ARMD) Drugs Segment by Type
1.2.2 Age-relatedMacularDegeneration (ARMD) Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Manufacturers (2019-2024)
3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Age-relatedMacularDegeneration (ARMD) Drugs Sales Sites, Area Served, Product Type
3.6 Age-relatedMacularDegeneration (ARMD) Drugs Market Competitive Situation and Trends
3.6.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Age-relatedMacularDegeneration (ARMD) Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Age-relatedMacularDegeneration (ARMD) Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Type (2019-2024)
6.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Price by Type (2019-2024)
7 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Sales by Application (2019-2024)
7.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Growth Rate by Application (2019-2024)
8 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET SEGMENTATION BY REGION
8.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region
8.1.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region
8.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Roche
9.1.1 Roche Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.1.2 Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.1.4 Roche Business Overview
9.1.5 Roche Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
9.1.6 Roche Recent Developments
9.2 Regeneron Pharmaceuticals
9.2.1 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.2.2 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.2.4 Regeneron Pharmaceuticals Business Overview
9.2.5 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
9.2.6 Regeneron Pharmaceuticals Recent Developments
9.3 Bayer
9.3.1 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.3.2 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.3.4 Bayer Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
9.3.5 Bayer Business Overview
9.3.6 Bayer Recent Developments
9.4 Santen Oy
9.4.1 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.4.2 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.4.4 Santen Oy Business Overview
9.4.5 Santen Oy Recent Developments
9.5 Kanghong Pharmaceuticals
9.5.1 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.5.2 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.5.4 Kanghong Pharmaceuticals Business Overview
9.5.5 Kanghong Pharmaceuticals Recent Developments
9.6 Novartis
9.6.1 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.6.2 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.6.4 Novartis Business Overview
9.6.5 Novartis Recent Developments
9.7 Eli Lilly and Company
9.7.1 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.7.2 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.7.4 Eli Lilly and Company Business Overview
9.7.5 Eli Lilly and Company Recent Developments
9.8 TRACON Pharmaceuticals
9.8.1 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.8.2 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.8.4 TRACON Pharmaceuticals Business Overview
9.8.5 TRACON Pharmaceuticals Recent Developments
9.9 Pfizer
9.9.1 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.9.2 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.9.4 Pfizer Business Overview
9.9.5 Pfizer Recent Developments
9.10 GSK
9.10.1 GSK Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.10.2 GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.10.4 GSK Business Overview
9.10.5 GSK Recent Developments
9.11 BIOCAD
9.11.1 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
9.11.2 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
9.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Market Performance
9.11.4 BIOCAD Business Overview
9.11.5 BIOCAD Recent Developments
10 AGE-RELATEDMACULARDEGENERATION (ARMD) DRUGS MARKET FORECAST BY REGION
10.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast
10.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Region
10.2.4 South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Age-relatedMacularDegeneration (ARMD) Drugs by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Age-relatedMacularDegeneration (ARMD) Drugs by Type (2025-2030)
11.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Age-relatedMacularDegeneration (ARMD) Drugs by Type (2025-2030)
11.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) Forecast by Application
11.2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Age-relatedMacularDegeneration (ARMD) Drugs Market Size Comparison by Region (M USD)
Table 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2022)
Table 10. Global Market Age-relatedMacularDegeneration (ARMD) Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Age-relatedMacularDegeneration (ARMD) Drugs Sales Sites and Area Served
Table 12. Manufacturers Age-relatedMacularDegeneration (ARMD) Drugs Product Type
Table 13. Global Age-relatedMacularDegeneration (ARMD) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Age-relatedMacularDegeneration (ARMD) Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
Table 22. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Type (K Units)
Table 23. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (M USD)
Table 24. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) by Type (2019-2024)
Table 25. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Type (2019-2024)
Table 28. Global Age-relatedMacularDegeneration (ARMD) Drugs Price (USD/Unit) by Type (2019-2024)
Table 29. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) by Application
Table 30. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
Table 31. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Application (2019-2024) & (K Units)
Table 32. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2019-2024)
Table 35. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country (2019-2024) & (K Units)
Table 39. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region (2019-2024) & (K Units)
Table 41. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region (2019-2024) & (K Units)
Table 43. Roche Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 44. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 45. Roche Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Roche Business Overview
Table 47. Roche Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
Table 48. Roche Recent Developments
Table 49. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 50. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 51. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Regeneron Pharmaceuticals Business Overview
Table 53. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
Table 54. Regeneron Pharmaceuticals Recent Developments
Table 55. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 56. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 57. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Bayer Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
Table 59. Bayer Business Overview
Table 60. Bayer Recent Developments
Table 61. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 62. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 63. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Santen Oy Business Overview
Table 65. Santen Oy Recent Developments
Table 66. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 67. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 68. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Kanghong Pharmaceuticals Business Overview
Table 70. Kanghong Pharmaceuticals Recent Developments
Table 71. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 72. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 73. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Novartis Business Overview
Table 75. Novartis Recent Developments
Table 76. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 77. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 78. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Eli Lilly and Company Business Overview
Table 80. Eli Lilly and Company Recent Developments
Table 81. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 82. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 83. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. TRACON Pharmaceuticals Business Overview
Table 85. TRACON Pharmaceuticals Recent Developments
Table 86. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 87. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 88. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Pfizer Business Overview
Table 90. Pfizer Recent Developments
Table 91. GSK Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 92. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 93. GSK Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. GSK Business Overview
Table 95. GSK Recent Developments
Table 96. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 97. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 98. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. BIOCAD Business Overview
Table 100. BIOCAD Recent Developments
Table 101. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 102. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 103. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 104. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 105. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 106. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 107. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 108. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 109. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 110. South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 111. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 112. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 113. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 114. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 115. Global Age-relatedMacularDegeneration (ARMD) Drugs Price Forecast by Type (2025-2030) & (USD/Unit)
Table 116. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) Forecast by Application (2025-2030)
Table 117. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Age-relatedMacularDegeneration (ARMD) Drugs Market Size Comparison by Region (M USD)
Table 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2022)
Table 10. Global Market Age-relatedMacularDegeneration (ARMD) Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Age-relatedMacularDegeneration (ARMD) Drugs Sales Sites and Area Served
Table 12. Manufacturers Age-relatedMacularDegeneration (ARMD) Drugs Product Type
Table 13. Global Age-relatedMacularDegeneration (ARMD) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Age-relatedMacularDegeneration (ARMD) Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges
Table 22. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Type (K Units)
Table 23. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (M USD)
Table 24. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) by Type (2019-2024)
Table 25. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Type (2019-2024)
Table 28. Global Age-relatedMacularDegeneration (ARMD) Drugs Price (USD/Unit) by Type (2019-2024)
Table 29. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) by Application
Table 30. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application
Table 31. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Application (2019-2024) & (K Units)
Table 32. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2019-2024)
Table 35. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country (2019-2024) & (K Units)
Table 39. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region (2019-2024) & (K Units)
Table 41. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales by Region (2019-2024) & (K Units)
Table 43. Roche Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 44. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 45. Roche Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Roche Business Overview
Table 47. Roche Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
Table 48. Roche Recent Developments
Table 49. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 50. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 51. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Regeneron Pharmaceuticals Business Overview
Table 53. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
Table 54. Regeneron Pharmaceuticals Recent Developments
Table 55. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 56. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 57. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Bayer Age-relatedMacularDegeneration (ARMD) Drugs SWOT Analysis
Table 59. Bayer Business Overview
Table 60. Bayer Recent Developments
Table 61. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 62. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 63. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Santen Oy Business Overview
Table 65. Santen Oy Recent Developments
Table 66. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 67. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 68. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Kanghong Pharmaceuticals Business Overview
Table 70. Kanghong Pharmaceuticals Recent Developments
Table 71. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 72. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 73. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Novartis Business Overview
Table 75. Novartis Recent Developments
Table 76. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 77. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 78. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Eli Lilly and Company Business Overview
Table 80. Eli Lilly and Company Recent Developments
Table 81. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 82. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 83. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. TRACON Pharmaceuticals Business Overview
Table 85. TRACON Pharmaceuticals Recent Developments
Table 86. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 87. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 88. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Pfizer Business Overview
Table 90. Pfizer Recent Developments
Table 91. GSK Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 92. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 93. GSK Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. GSK Business Overview
Table 95. GSK Recent Developments
Table 96. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Basic Information
Table 97. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Overview
Table 98. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. BIOCAD Business Overview
Table 100. BIOCAD Recent Developments
Table 101. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 102. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 103. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 104. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 105. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 106. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 107. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 108. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 109. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 110. South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 111. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 112. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 113. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 114. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 115. Global Age-relatedMacularDegeneration (ARMD) Drugs Price Forecast by Type (2025-2030) & (USD/Unit)
Table 116. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) Forecast by Application (2025-2030)
Table 117. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Age-relatedMacularDegeneration (ARMD) Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD), 2019-2030
Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (M USD)
Figure 11. Age-relatedMacularDegeneration (ARMD) Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Manufacturers in 2023
Figure 13. Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Age-relatedMacularDegeneration (ARMD) Drugs Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type
Figure 18. Sales Market Share of Age-relatedMacularDegeneration (ARMD) Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Age-relatedMacularDegeneration (ARMD) Drugs by Type in 2023
Figure 20. Market Size Share of Age-relatedMacularDegeneration (ARMD) Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Age-relatedMacularDegeneration (ARMD) Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application
Figure 24. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application in 2023
Figure 26. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2019-2024)
Figure 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application in 2023
Figure 28. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Country in 2023
Figure 37. Germany Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region in 2023
Figure 44. China Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (K Units)
Figure 50. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Age-relatedMacularDegeneration (ARMD) Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD), 2019-2030
Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country (M USD)
Figure 11. Age-relatedMacularDegeneration (ARMD) Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Manufacturers in 2023
Figure 13. Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Age-relatedMacularDegeneration (ARMD) Drugs Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type
Figure 18. Sales Market Share of Age-relatedMacularDegeneration (ARMD) Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Age-relatedMacularDegeneration (ARMD) Drugs by Type in 2023
Figure 20. Market Size Share of Age-relatedMacularDegeneration (ARMD) Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Age-relatedMacularDegeneration (ARMD) Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application
Figure 24. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application in 2023
Figure 26. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2019-2024)
Figure 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application in 2023
Figure 28. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Age-relatedMacularDegeneration (ARMD) Drugs Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Country in 2023
Figure 37. Germany Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region in 2023
Figure 44. China Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (K Units)
Figure 50. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share Forecast by Application (2025-2030)
